

Press Release

Astellas Announces Cancellation of Treasury Shares

Tokyo, April 25, 2019 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D.) today announced that at the meeting of the Board of Directors held today, a resolution was adopted that the Company will cancel its treasury shares, pursuant to Article 178 of the Companies Act.

Particulars

- | | |
|-------------------------------------|---|
| 1. Class of shares to be cancelled | Common stock of the Company |
| 2. Number of shares to be cancelled | 91 million shares
(Representing 4.60% of issued shares
prior to cancellation) |
| 3. Cancellation date | May 31, 2019 |

(Reference)

1. Following cancellation, the Company will have 1,888,823,175 issued shares.
2. Total number of the Company's treasury shares after cancellation will be 2,986,348.

(Expected numbers of shares described above 1 and 2 were calculated on the basis of the issued shares and the Company's treasury shares as of March 31, 2019, respectively.)

###

About Astellas

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. For more information, please visit our website at <https://www.astellas.com/en>

Cautionary Notes

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

###

Contacts for inquiries or additional information:

Astellas Pharma Inc.
Corporate Communications
TEL: +81-3-3244-3201 FAX: +81-3-5201-7473